ABS-101 (anti-TL1A)
Phase 1 per company
Since , the date of the source that reports this phase.
Summary
ABS-101 is an anti-TL1A from Absci. The source describes it as antibody. It is being developed for inflammatory bowel disease (TL1A). Per the company, it was at Phase 1 as of May 13, 2025. The AI role named in the source is antibody design. About the company, based in United States: Integrated Drug Creation platform combining generative AI with wet-lab validation to design antibodies; lead ABS-201 (anti-PRLR) is in Phase 1/2. First participants dosed. The latest dated source is from May 13, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Absci
- Indication
- Inflammatory bowel disease (TL1A)
- Therapeutic area
- Immunology and inflammation
- Modality
- Antibody
- AI role
- Antibody design
- Phase in the source
- Phase 1, as of May 13, 2025
- Phase source
- X only
- Board column
- Phase 1
- Trial record
- none found on CT.gov, EU CTIS or ANZCTR
Key readouts in the source
First participants dosed
AI evidence
AI source: Company
“Absci used its de novo AI model to design ABS-101 toward a specific epitope”
Milestone timeline
-
Official X post: Phase 1
First participants dosed
About Absci
Integrated Drug Creation platform combining generative AI with wet-lab validation to design antibodies; lead ABS-201 (anti-PRLR) is in Phase 1/2.
Spot an error? Tell me and I'll fix it.